1. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network Ginsburg GS, Cavallari LH, Chakraborty H, et al. Genetics in Medicine. 2021. DOI: 10.1038/s41436-021-01118-9. 

2. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems Hicks JK, El Rouby N, Ong HH, et al. Clinical Pharmacology & Therapeutics. 2021. DOI: 10.1002/cpt.2161. 

3. Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey Owusu Obeng A, Fei K, Levy KD, et al. Journal of Personalized Medicine. 2018. DOI: 10.3390/jpm8030024.

4. The. Study tag: IGNITE Network,: a model for genomic medicine implementation and research Weitzel KW, Alexander M, Bernhardt BA, et al. BMC Medical Genomics. 2016. DOI: 10.1186/s12920-015-0162-5. 

1. CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone Lteif C, Cavallari LH. Frontiers in Pharmacology. 2026. DOI: 10.3389/fphar.2026.1817652. 

2. Genotype-Guided Antidepressant Prescribing for Patients With Depression Blake KV, Hines LJ, Liu M. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2026.10609. 

3. CYP2D6-Guided Opioid Management and Postoperative Pain Control Cavallari LH, Myers RA, Chakraborty H. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2025.58299. 

4. Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators Skaar TC, Myers RA, Fillingim RB, et al. Clinical and Translational Science. 2024. DOI: 10.1111/cts.70005.

5. Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression Hines LJ, Wilke RA, Myers R, et al. Clinical and Translational Science. 2024. DOI: 10.1111/cts.13822.

6. Implementing a Pragmatic Clinical Trial to Tailor Opioids for Acute Pain on behalf of the IGNITE ADOPT PGx Investigators Cavallari LH, Cicali E, Wiisanen K, et al. Clinical and Translational Science. 2022. DOI: 10.1111/cts.13376.

7. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy Tuteja S, Salloum RG, Elchynski AL, et al. Clinical and Translational Science. 2022. DOI: 10.1111/cts.13154.

8. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing Duarte JD, Dalton R, Elchynski AL, et al. Genetics in Medicine. 2021. DOI: 10.1038/s41436-021-01269-9. 

9. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network Ginsburg GS, Cavallari LH, Chakraborty H, et al. Genetics in Medicine. 2021. DOI: 10.1038/s41436-021-01118-9. 

10. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems Hicks JK, El Rouby N, Ong HH, et al. Clinical Pharmacology & Therapeutics. 2021. DOI: 10.1002/cpt.2161. 

11. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients Ramsey LB, Ong HH, Schildcrout JS, et al. JAMA Network Open. 2020. DOI: 10.1001/jamanetworkopen.2020.29411.

12. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention Lee CR, Thomas CD, Beitelshees AL, et al. Clinical Pharmacology & Therapeutics. 2021. DOI: 10.1002/cpt.2039.

13. Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey Owusu Obeng A, Fei K, Levy KD, et al. Journal of Personalized Medicine. 2018. DOI: 10.3390/jpm8030024.

14. The. Study tag: IGNITE Network,: a model for genomic medicine implementation and research Weitzel KW, Alexander M, Bernhardt BA, et al. BMC Medical Genomics. 2016. DOI: 10.1186/s12920-015-0162-5. 

1. Genetic Testing for APOL1 in Adults With Hypertension – The GUARDD-US Randomized Clinical Trial Eadon MT, Cavanaugh KL, She L. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2026.0528.

2. Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension Eadon MT, Cavanaugh KL, Orlando LA, et al. Contemporary Clinical Trials. 2022. DOI: 10.1016/j.cct.2022.106813.

3. Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial Nadkarni GN, Fei K, Ramos MA, et al. JAMA Network Open. 2022. DOI: 10.1001/jamanetworkopen.2022.1048.

4. CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings Beitelshees AL, Thomas CD, Empey PE, et al. Journal of the American Heart Association. 2022. DOI: 10.1161/JAHA.121.024159. 

5. Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management Schneider TM, Eadon MT, Cooper-DeHoff RM, et al. Journal of Personalized Medicine. 2021. DOI: 10.3390/jpm11060480.

6. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network Ginsburg GS, Cavallari LH, Chakraborty H, et al. Genetics in Medicine. 2021. DOI: 10.1038/s41436-021-01118-9. 

7. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems Hicks JK, El Rouby N, Ong HH, et al. Clinical Pharmacology & Therapeutics. 2021. DOI: 10.1002/cpt.2161. 

8. Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey Owusu Obeng A, Fei K, Levy KD, et al. Journal of Personalized Medicine. 2018. DOI: 10.3390/jpm8030024.

9. Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry Horowitz CR, Abul-Husn NS, Ellis S, et al. Contemporary Clinical Trials. 2016. DOI: 10.1016/j.cct.2015.12.020.

10. The. Study tag: IGNITE Network,: a model for genomic medicine implementation and research Weitzel KW, Alexander M, Bernhardt BA, et al. BMC Medical Genomics. 2016. DOI: 10.1186/s12920-015-0162-5.